For this, we used an MTAP/CDKN2B-AS1 deletion (MA-del) assay to examine various EJ outcomes via the chromosomal deletion rearrangement of the CDKN2A gene, a common deletion rearrangement found in various cancer types (Fig. 2A)51,52. The gene discussed is CDKN2B; the disease is cancer.